EyePoint Pharmaceuticals (EYPT) Cash from Operations: 2010-2024
Historic Cash from Operations for EyePoint Pharmaceuticals (EYPT) over the last 15 years, with Dec 2024 value amounting to -$126.2 million.
- EyePoint Pharmaceuticals' Cash from Operations fell 25753.09% to -$20.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$45.8 million, marking a year-over-year decrease of 67.12%. This contributed to the annual value of -$126.2 million for FY2024, which is 6832.05% down from last year.
- According to the latest figures from FY2024, EyePoint Pharmaceuticals' Cash from Operations is -$126.2 million, which was down 6,832.05% from $1.9 million recorded in FY2023.
- EyePoint Pharmaceuticals' 5-year Cash from Operations high stood at $1.9 million for FY2023, and its period low was -$126.2 million during FY2024.
- Moreover, its 3-year median value for Cash from Operations was -$65.0 million (2022), whereas its average is -$63.1 million.
- As far as peak fluctuations go, EyePoint Pharmaceuticals' Cash from Operations skyrocketed by 102.88% in 2023, and later plummeted by 6,832.05% in 2024.
- Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Cash from Operations stood at -$14.4 million in 2020, then slumped by 247.05% to -$50.1 million in 2021, then decreased by 29.76% to -$65.0 million in 2022, then spiked by 102.88% to $1.9 million in 2023, then slumped by 6,832.05% to -$126.2 million in 2024.